These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Silberstein SD; Collins SD Headache; 1999 Oct; 39(9):633-43. PubMed ID: 11284461 [TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. Wagner KD; Redden L; Kowatch RA; Wilens TE; Segal S; Chang K; Wozniak P; Vigna NV; Abi-Saab W; Saltarelli M J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):519-532. PubMed ID: 19325497 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471 [TBL] [Abstract][Full Text] [Related]
8. Divalproex sodium extended-release for the prophylaxis of migraine headache. Freitag FG Expert Opin Pharmacother; 2003 Sep; 4(9):1573-8. PubMed ID: 12943487 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Caruso JM; Brown WD; Exil G; Gascon GG Headache; 2000 Sep; 40(8):672-6. PubMed ID: 10971664 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
11. Divalproex sodium in the treatment of migraine and cluster headaches. Gallagher RM; Mueller LL; Freitag FG J Am Osteopath Assoc; 2002 Feb; 102(2):92-4. PubMed ID: 11866398 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. Redden L; DelBello M; Wagner KD; Wilens TE; Malhotra S; Wozniak P; Vigna NV; Greco N; Kovacs X; Abi-Saab W; Saltarelli M; J Child Adolesc Psychopharmacol; 2009 Feb; 19(1):83-9. PubMed ID: 19232026 [TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [TBL] [Abstract][Full Text] [Related]
18. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478 [TBL] [Abstract][Full Text] [Related]
19. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549 [TBL] [Abstract][Full Text] [Related]
20. Divalproex in the treatment of migraine. Freitag FG Psychopharmacol Bull; 2003; 37 Suppl 2():98-115. PubMed ID: 15021865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]